Skip to main content
OpenTrials
Completed

NCT Number: NCT07239453

Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects

This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–44 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

CHA University Bundang Medical Center

Seongnam-si, Gyeonggi-do, 13520, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • BMI between 18 and 30 kg/m2
  • Body weight: Male≥50kg, Female≥45kg
  • Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study

Exclusion criteria

  • Subjects with clinically significant medical history
  • Subjects with history of drug abuse or addicted
  • Subjects with allergy or drug hypersensitivity

Treatment and study plan

DA-2902

Drug

single dose administration (DA-2902 one tablet once a day)

DA-2902-R

Drug

single dose administration (DA-2902-R one tablet once a day)

Primary outcomes

  1. AUCt

    Time frame: pre-dose ~ 72 hr of pose-dose

  2. Cmax

    Time frame: pre-dose ~ 72 hr of post-dose

Sponsors and collaborators

Lead sponsor

Dong-A ST Co., Ltd.

Industry

Registry information

Official study title

An Open-Label, Randomized, Single Oral Dose, Two-Sequence, Two-Period, CrossovSer Bioequivalence Study of "DA-2902" and "DA-2902-R" in Healthy Adults Under Fed Conditions

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Nov 20, 2025
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.